Arcadia Biosciences, Inc. (NASDAQ:RKDA – Get Rating) – Equities researchers at  HC Wainwright issued their Q1 2024 earnings estimates for shares of Arcadia Biosciences  in a note issued to investors on  Friday, April 14th. HC Wainwright analyst R. Selvaraju anticipates that the basic materials company will post earnings per share of ($2.70) for the quarter. HC Wainwright  has a “Buy” rating and a $18.00 price objective on the stock. HC Wainwright also issued estimates for Arcadia Biosciences’ Q2 2024 earnings at ($1.76) EPS, Q3 2024 earnings at ($1.30) EPS, Q4 2024 earnings at ($1.24) EPS and FY2024 earnings at ($6.43) EPS.

A number of other equities analysts have also weighed in on the stock. Lake Street Capital cut their price objective on shares of Arcadia Biosciences from $80.00 to $20.00 in a research report on Friday, March 31st. StockNews.com began coverage on shares of Arcadia Biosciences in a research note on Friday, April 14th. They issued a “sell” rating for the company.

RKDA stock opened at $6.93 on Monday. The company has a market cap of $5.96 million, a P/E ratio of -0.27 and a beta of 1.00. Arcadia Biosciences has a 52 week low of $6.52 and a 52 week high of $60.00. The company’s 50-day moving average price is $5.41 and its 200 day moving average price is $2.13.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC grew its holdings in  Arcadia Biosciences by 444.3% during the fourth quarter. Millennium Management LLC now owns 185,438 shares of the basic materials company’s stock valued at $50,000 after purchasing an additional 151,371 shares during the last quarter.  Susquehanna International Group LLP raised its holdings in shares of  Arcadia Biosciences by 85.1% in the fourth quarter. Susquehanna International Group LLP now owns 282,419 shares of the basic materials company’s stock valued at $77,000 after buying an additional 129,811 shares during the last quarter.  Armistice Capital LLC bought a new stake in  Arcadia Biosciences during the 3rd quarter worth about $850,000.  Renaissance Technologies LLC raised its holdings in  Arcadia Biosciences by 66.5% during the 2nd quarter. Renaissance Technologies LLC now owns 129,500 shares of the basic materials company’s stock worth $130,000 after purchasing an additional 51,700 shares during the last quarter.  Finally, Jane Street Group LLC raised its holdings in  Arcadia Biosciences by 215.8% during the 1st quarter. Jane Street Group LLC now owns 36,458 shares of the basic materials company’s stock worth $51,000 after purchasing an additional 24,913 shares during the last quarter. 13.33% of the stock is currently owned by institutional investors and hedge funds.

Arcadia Biosciences, Inc is an agricultural biotechnology company, which engages in the development of agricultural products. It uses screening, breeding, and biotechnology techniques to create agricultural products for consumers, processors, and farmers. Its products include GoodWheat pasta, Zola coconut water, ProVault topical pain relief, and SoulSpring bath and body care.

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.